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1. Introduction 
Genotoxic compounds induce genetic mutations and/or chromosomal rearrangements and 
can therefore act as carcinogenic compounds (McGovern and Jacobson-Kram, 2006). These 
compounds cause damage to DNA by different mechanisms such as alkylation or other 
interactions that can lead to mutation of the genetic codes. In general, chemists employ the 
terms "genotoxic" and "mutagenic" synonymously; however, there is a subtle distinction. 
Genotoxicity pertains to all types of DNA damage (including mutagenicity), whereas 
mutagenicity pertains specifically to mutation induction at the gene and chromosome levels. 
Thus, the term “genotoxic” is applied to agents that interact with DNA and/or its associated 
cellular components (e.g. the spindle apparatus) or enzymes (e.g. topoisomerases) (Dearfield 
et al., 2002; Robinson, 2010). Irrespective of the mechanism by which cancer is induced, it is 
now well agreed that it involves a change in the integrity or expression of genomic DNA. 
The majority of chemical carcinogens are capable of causing DNA damage, i.e., are 
"genotoxic" (Ashby, 1990). Moreover, a genotoxic compound also carries with it the 
carcinogenic effect which causes additional concern from the safety viewpoint. 
Drug substances and their relative compounds such as impurities constitute an important 
group of genotoxic compounds. Thus, these compounds pose an additive concern to clinical 
subjects and patients (Müller et al., 2006). Considering the importance of this problem, the 
challenge for regulatory agencies is to form guidelines and standards for the identification 
and control of genotoxic compounds and their impurities especially in pharmaceuticals. In 
this article, genotoxicity profiles of the main group of genotoxic compounds are discussed. 
The article throws light on the challenges in analyzing and predicting for these groups and 
also deals with the different management problems of genotoxic impurities in 
pharmaceuticals. 
2. Guidelines 
2.1 ICH guidelines 
The International Conference on Harmonization (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use project represents the main group of 
guidelines with topics such as "Quality" topics and "Safety" topics. Quality topics relate to 
chemical and pharmaceutical quality assurance (stability testing, impurity testing, etc.) and 
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safety topics deal with in vitro and in vivo pre-clinical studies (carcinogenicity testing, 
genotoxicity testing, etc.) (ICH, 2008). 
The ICH initially published guidelines on impurities of drug substances and pharmaceutical 
products in the late 1990s. In the guidelines, genotoxicity tests have been defined as in vitro 
and in vivo tests designed for detecting compounds that induce genetic damage directly or 
indirectly (International Conference on Harmonization, 1997). The ICH quality guidelines 
Q3A(R) and Q3B(R) respectively address the topics of control of impurities in drug 
substances and degradants in pharmaceutical products, while the Q3C guideline deals with 
the residual solvents. However, several important issues have not been addressed in the 
guidelines, for example, the acceptable levels of impurities in drugs during development as 
well as the control of genotoxic impurities. Table 1 illustrates a series of thresholds described 
in ICH Q3A(R) that trigger reporting, identification, and qualification requirements. 
Subsequently, Table 2 depicts the thresholds for reporting, identification, and qualification 
of impurities in new drug products (ICH, 2006; Jacobson-Kram and McGovern, 2007). In 
addition, two options for standard test battery for genotoxicity are available in the ICH S2 
(R1) guideline (ICH,  2008): 
 
Thresholds 
Maximum daily dose 
≤2 g/day >2 g/day 
Reporting  threshold 0.05% 0.03% 
Identification threshold 
0.10% or 1.0 mg per day intake  
(whichever is lower) 
0.05% 
Qualification threshold 
0.15% or 1.0 mg per day intake  
(whichever is lower) 
0.05% 
Table 1. Threshold for APIs  
Option 1 
i. A test for gene mutation in bacteria; 
ii. A cytogenetic test for chromosomal damage (the in vitro metaphase chromosome 
aberration test or in vitro micronucleus test), or an in vitro mouse lymphoma tk gene 
mutation assay; 
iii. An in vivo test for genotoxicity, generally a test for chromosomal damage using rodent 
hematopoietic cells, either for micronuclei or for chromosomal aberrations in metaphase 
cells. 
Option 2 
i. A test for gene mutation in bacteria; 
ii. An in vivo assessment of genotoxicity with two tissues, usually an assay for micronuclei 
using rodent hematopoietic cells and a second in vivo assay. 
As stated by the ICH safety guidelines (S2A and S2B), "for compounds giving negative 
results, the completion of 3-test battery, perform and evaluate in accordance with current 
recommendations, will usually provide a sufficient level of safety to demonstrate the 
absence of genotoxic activity." Thus, any compound that produces a positive result in one or 
more assays in the standard battery has historically been regarded as genotoxic, which may 
require further testing for risk assessment (Müller et al., 2006). 
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Maximum 
Daily Dose1 
Reporting 
Thresholds2,3 
Identification Thresholds2,3 Qualification Thresholds2,3 
≤ 1 mg  1.0% or 5 g TDI  
whichever is lower 
 
1 – 10 mg  0.5% or 20 g TDI  
whichever is lower 
 
10 – 100 mg   0.5% or 200 g TDI 
whichever is lower 
<10 mg   1.0% or 50 g TDI 
whichever is lower 
> 10 mg - 2 g  0.2% or 2 mg TDI  
whichever is lower 
 
> 100 mg – 2 g   0.2% or 3 mg TDI  
whichever is lower 
≤1 g 0.1 %   
> 1 g 0.05 %   
> 2 g  0.1%  
> 2 g   0.15% 
1 The amount of drug substance administered per day 
2Thresholds for degradation products are expressed either as a percentage of the drug substance or as a 
total daily intake (TDI) of the degradation product. Lower thresholds can be appropriate if the 
degradation product is unusually toxic. 
3Higher thresholds should be scientifically justified. 
Table 2. Thresholds for degradation products in new drug products (Jacobson-Kram and 
McGovern, 2007) 
2.2 EMEA guideline 
The European Medicines Agency (EMEA) guideline describes a general framework and 
practical approaches on how to deal with genotoxic impurities in new active substances. 
According to the guideline "The toxicological assessment of genotoxic impurities and the 
determination of acceptable limits for such impurities in active substances is a difficult issue 
and not addressed in sufficient detail in the existing ICH Q3X guidance". In addition, the 
EMEA guideline proposed a toxicological concern (TTC) threshold value of 1.5 μg/day intake 
of a genotoxic impurity which is considered to be associated with an acceptable risk (excess 
cancer risk of <1 in 100,000 over a lifetime) in most pharmaceuticals. Based on the TTC value, a 
permitted level of an active substance can be calculated concerning the expected daily dose. 
Higher limits might be justified under certain conditions such as short-term exposure periods 
(European Medicines Agency/ Committee for Medicinal Products (CHMP) for Human Use, 
2006). In the context of this guideline, the classification of a compound (impurity) as genotoxic 
in general indicates that there are positive findings in established in vitro or in vivo genotoxicity 
tests with the focus on DNA reactive substances that have a potential for direct DNA damage. 
In the absence of such information, in vitro genotoxics are usually considered as presumptive 
in vivo mutagens and carcinogens (EMEA/CHMP, 2006). 
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Based on the importance of the mechanism of action and the dose-response relationship in 
the assessment of genotoxic compounds, the EMEA guideline presents two classes of 
genotoxic compounds: 
1. Genotoxic compounds with sufficient (experimental) evidence for a threshold-related 
mechanism, 
2. Genotoxic compounds without sufficient (experimental) evidence for a threshold-
related mechanism. 
Those genotoxic compounds with sufficient evidence would be regulated according to the 
procedure as outlined for class 2 solvents in the “Q3C Note for Guidance on Impurities: 
Residual Solvents”. For genotoxic compounds without sufficient evidence for a threshold-
related mechanism, the guideline proposes a policy of controlling levels to “as low as 
reasonably practicable” (ALARP) principle, where avoiding is not possible.   
On the other hand, this guideline provides no advice on acceptable TTCs for drugs during 
development, especially for trials of short duration (Jacobson-Kram and McGovern, 2007).  
The pharmaceutical research and manufacturing association (PhRMA) has established a 
procedure for the testing, classification, qualification, toxicological risk assessment, and 
control of impurities processing genotoxic potential in pharmaceutical products. As most 
medicines are given for a limited period of time, this procedure proposes a staged TTC to 
adjust the limits for shorter exposure time during clinical trials (Table 3). Thus, the staged 
TTC can be used for genotoxic compounds having genotoxicity data that are normally not 
suitable for a quantitative risk assessment (Muller et al., 2006). 
 
 Duration of clinical trial exposure 
≤ 1 
month 
> 1-3 
month 
> 3-6 
month 
>6-12 
month 
>12 
month 
Allowable Daily Intake 
(µg/day) for all phases of 
development 
120 60 20 10 1.5 
Alternative maximum level of 
allowable impurity based on 
percentage of impurity in API 
0.5% 0.5% 0.5% 0.5% 0.5% 
Table 3. PhRMA genotoxic impurity task force proposal – allowable daily intake (µg/day) 
for genotoxic impurities during clinical development using the staged TTC approach 
3. Genotoxic impurities (GIs) 
3.1 Sulfonates 
Sulfonate salts (Figure 1) are the most frequently used compounds in pharmaceutical 
developments. Salt formation is a useful technique for optimizing the physicochemical 
processing (formulation), biopharmaceutical or therapeutic properties of active 
pharmaceutical ingredients (APIs), and sulfonate salts are widely used for this purpose 
(Elder and Snodin,  2009). In addition to the advantages of processing, sulfonate salts 
possess some advantages over other salts such as producing higher melting point of the 
sulfonated API. This helps to enhance the stability and provide good solubility and may 
have certain in vivo advantages as well. For instance, in contrast to other salts of strong 
acids, mesylates do not have a tendency to form hydrates, which makes them an attractive 
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salt form for secondary processing, especially wet granulation. Another benefit of these salts 
is their high melting point because APIs with low melting points often exhibit plastic 
deformation during processing which can cause both caking and aggregation. Typically, an 
increase in the melting point has an adverse effect on aqueous solubility owing to an 
increase in the crystal lattice energies. Sulfonic acid salts tend to be an exception to this rule, 
since they exhibit both high melting points as well as good solubility. In addition, as 
mentioned in the literature, the high solubility and high surface area of haloperidol mesylate 
result in enhanced dissolution rates (<2 min in pH 2 simulated gastric media), which are 
more rapid than the competing common ion formation (Elder and Snodin, 2009; Elder et al., 
2010a).  
On the other hand, sulfonic acids can react with low molecular weight alcohols such as 
methanol, ethanol, or isopropanol to form the corresponding sulfonate esters. In general, 
sulfonic acid esters are considered as potential alkylating agents that may exert genotoxic 
effects in bacterial and mammalian cell systems and possibly carcinogenic effects in vivo; 
thus, these compounds have raised safety concerns in recent times (Snodin, 2006; Teasdale et 
al., 2009). 
 
                            
             Mesyla                               Tosylate                                Besylate 
Fig. 1. Structures of common sulfonate salts 
3.1.1 Genotoxicity profile 
Sulfonate impurities comprise the most investigated group of genotoxic impurities (GIs). 
Initially in 2007, sulfonate impurities raised major concern when over a period of three 
months (March to May 2007), several thousand HIV patients in Europe were exposed to 
ViraceptR (nelfinavir mesylate) tablets containing the contaminant ethyl methane sulfonate 
(EMS). However, the available in vitro and animal data indicated that the levels at which 
HIV patients were exposed to EMS (maximal dose of 0.055 mg/kg/d) did not induce any 
risk; nevertheless, any further level was of significant concern to their safety (Elder and 
Snodin, 2009). Since 2007 other drugs have been reported for contamination by sulfonate 
impurities, such as alkyl benzene sulfonates in amlodipine besylate (Raman et al., 2008), 
dimethyl sulfate (DMS) in pazopanib hydrochloride (Liu et al., 2009), EMS and methyl 
methane sulfonate (MMS) in imatinib mesylate (Ramakrishna et al., 2008), EMS in zugrastat 
(Schülé et al., 2010), alkyl sulfonates in flouroaryl-amine (Cimarosti et al., 2010), and ethyl 
besylate in UK-369,003-26, a novel PDE5 inhibitor (Hajikarimian et al., 2010). 
EMS is a well-established genotoxic agent in this group which reacts with DNA producing 
alkylated (specifically ethylated) nucleotides. MMS, an analog of EMS, is a genotoxic 
compound both in vitro and in vivo. The international agency for research on cancer (IARC) 
has classified EMS and MMS in group 2B and 2A, respectively (Snodin, 2006; Gocke et al., 
2009a). 
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Gocke et al. (2009a) reviewed both in vivo and in vitro genotoxicity, carcinogenicity, general 
toxicity, and the effects on reproductive and embryo fetal development of EMS. They 
reported that the genotoxic effects induced by EMS were observed in viruses/phages, 
bacteria, fungi, plant, insect, and mammalian cells. In another study, the induction of gene 
mutations at the hprt locus and the induction of chromosomal damage were examined as 
evidenced by the formation of micronuclei in human lymphoblastoid cells. It was found that 
the lowest dose inducing a positive response was 1.40 g/ml, and a no observed effect level 
(NOEL) could be defined at 1.2 g/ml. Also, no toxicity was observed at doses up to 2.5 
g/plate. This observation is in strong contrast to the largely linear dose–response observed 
in the previous studies. As a result of in vivo assays for the induction of DNA damage, EMS 
is distributed rather uniformly over the body and induces similar levels of DNA damage in 
the various organs. Also, EMS is clastogenic in all test systems. The minimal dose of EMS 
applied in these studies was either 50 mg/kg or 100 mg/kg. In the majority of studies the 
dose–response relationships appeared sub linear and a threshold below 50 mg/kg appeared 
possible. Gocke et al. (2009a) demonstrated that EMS in various gene mutation tests such as 
induction of hprt, lacZ, and dlb-1 mutations in mice was mutagenic. The carcinogenicity of 
EMS was confirmed in several animal models. In another study, three methanesulfonates 
and three benzenesulfonates were tested by micronucleus and Yeast deletion recombination 
(DEL) assays. It was observed that all six substances produced positive responses in the tests 
(Sobol et al., 2007).   
3.2 Alkyl halides and esters 
Owing to their electrophilic nature, alkylating agents can introduce lesions at nucleophilic 
centers of DNA. Drug salt formation includes strong acid/base interactions in the presence 
of alcohols, and can form impurities such as alkyl halides. As salt formation is a common 
method in drug formulation processes, alkyl halides exist as impurities in several drugs 
(Sobol et al., 2007; Elder et al., 2008a). 
3.2.1 Genotoxicity profile 
The nucleophilic attack mechanisms of alkylating compounds determine their reactivity 
against DNA. The SN1 mechanism leads to O-alkylation (O-6-methylguanine) which is 
mutagenic but not clastogenic, whereas the SN2 mechanism leads to N-methylation which is 
clastogenic and not mutagenic. In this group, it seems that bromo compounds are more 
reactive as compared to chloro compounds (Sobol et al., 2007; Snodin, 2010). 
Various tests have been performed to study DNA damage and mutation in alkyl halides. In 
the Ames test, it was found that most alkyl halides, especially bromides, are Ames positive 
except 1-chloropropane, 1-chlorobutane, and neopentyl bromide. As chloro- and 
bromobenzene are not alkylating agents, these compounds are Ames-negative. In Yeast 
deletion recombination (DEL) and micronucleus assays, alkyl chlorides such as n-propyl 
chloride are found to be negative (Sobol et al., 2007; Snodin, 2010). 
It was observed that alkyl chlorides in the NBP [4-(p nitrobenzyl) pyridine] alkylation assay 
are not reactive and that allyl chloride has minimal activity. Although benzyl chloride is 
more active than other chloro compounds, ethyl, propyl, or butyl bromides have at least 
1/40 MMS activity; however, allyl bromide appears to be more active (around one-eighth of 
the activity of MMS) (Sobol et al., 2007). 
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As indicated by the in vivo test in rodent bioassay, these compounds are either non-
carcinogens (1- chlorobutane, bromomethane) or low-potency carcinogens (chloroethane, 
bromoethane). According to in vivo tests, chloroethane and alkyl bromides seem to be non-
genotoxic carcinogens rather than genotoxic carcinogens. Based on the available data, the 
United States environmental protection agency (USEPA), considers tert-butyl chloride to be 
a group D compound or ‘‘not classifiable as to human carcinogenicity’’ (Bercu et al., 2009; 
Snodin, 2010). 
3.3 Hydrazines  
Hydrazine is used as a medicine or as a starting compound for synthesizing some 
medicines. Hydrazine and some of its N-alkyl, N-aryl, and N-acyl analogues have been 
subjected to extensive toxicological evaluations. Hydrazines, hydrazides, and hydrazones 
have structural alerts for genotoxic potential and the metabolism increases their effects. 
Hydrazines adduct with DNA and the mechanism of adduction could include the formation 
of methyldiazanium ions or methyl free radicals. In addition, it seems that hydrazine reacts 
with endogenous formaldehyde to produce formaldehyde hydrazone. Subsequent to some 
other reactions, alkylating compounds like diazomethane as the genotoxic moiety are 
produced (Bercu et al., 2009; Snodin, 2010). 
3.3.1 Genotoxicity profile 
In vitro studies have shown genotoxic effects for three hydrazine derivatives (hydrazines, 
hydrazides, and hydrazones). These compounds induce gene mutations in human teratoma 
cells, mouse lymphoma cells, and in several strains of bacteria. Hydralazine (1-
hydrazinylphthalazine) and its hydrochloride salt are Ames-positive. In another study, 20 
hydrazine-derivatives were found to induce a direct DNA damage in Escherichia coli and 16 
of them (80%) were Ames positive as well (Flora et al., 1984; Agency for Toxic Substance and 
Disease Registry, 1997; Snodin, 2010). 
Although it was seen that hydrazine did not induce unscheduled DNA synthesis in mouse 
sperm cells, in vivo studies on the genotoxicity of hydrazines have largely produced positive 
results. In addition, it was observed that 1, 2-dimethylhydrazine failed to induce 
micronuclei in rat bone marrow cells, while this effect had been observed in mouse bone 
marrow cells (Agency for Toxic Substance and Disease Registry, 1997). 
The non-carcinogenic effects of hydrazine were also evaluated; however, it was found that 
hydrazine, methyl hydrazine, 1,1- and 1,2-dimethylhydrazine, and other analogues are 
carcinogenic in rodents and possibly in human. In addition, it was seen that hydrazine 
derivatives like hydralazine and its hydrochloride salt were tumorigenic in rodents. It 
should be mentioned that the clinical use of hydralazine hydrochloride for several years has 
shown no evidence for carcinogenicity (Flora et al., 1984; Bercu et al., 2009; Snodin, 2010).  
3.4 Epoxides 
Epoxides are considered as electrophilic compounds owing to the strained epoxide ring. 
These alkylating agents directly react with DNA. Alkene oxides are more reactive than 
arene oxides and symmetrically substituted epoxides are less reactive than asymmetrically 
substituted compounds. Some examples for APIs with epoxide impurities are 
betamethasone acetate, atenolol, and some herbal remedies. Carbamazepine, 
cyproheptadine, and protriptyline have stable epoxide metabolites. In addition, phenytoin, 
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lamotrigine, amitryptiline, and diclofenac tend to form reactive arene oxide metabolic 
intermediates (Flora et al., 1984; Elder et al., 2010b; Snodin, 2010).  
The metabolism of epoxides mainly involves epoxide hydrolase (EH) and glutathione S-
transferase (GST), which leads to either detoxification or production of epoxides. These 
pathways play a key role in the genotoxic action of epoxides (Snodin, 2010). 
3.4.1 Genotoxicity profile 
As indicated in in vitro studies, epoxides are genotoxic in bacterial reverse mutation assays; 
however, other studies have shown different results. Hude et al. (1990) reported that 12/51 
epoxides were nongenotoxic in the Ames Salmonella assay. In this study, 51 epoxides were 
assessed with the SOS-Chromo test using Escherichia coli PQ37 followed by a comparison 
with the results of the Ames test. All compounds were tested with and without S9 mixture 
up to cytotoxicity. In tests without S9 mixture the SOS-repair induction of each experiment 
was controlled by the response to 4-nitroquinoline-N-oxide, and in tests with S9 mixture, it 
was controlled with benzo[a]pyrene. In the Ames test, 20 epoxides were tested for 
mutagenic activity with the Salmonella typhimurium strains TA100, TA1535, TA98, and 
TA1537.  By comparing the results of the Ames test and the SOS-Chromo test, it was found 
that among 51 epoxide-bearing chemicals 39 induced base-pair mutations in at least one 
Salmonella strain.  
Wade et al. (1978) studied the mutagenicity of 17 aliphatic epoxides using the specially 
constructed mutants of Salmonella typhimurium that were developed by Ames. It was found 
that all the compounds in the study, with the exception of 2-methyl-3,3,3-trichloropropylene 
oxide, cis-stilbene oxide, and cyclohexene oxide that were mutagenic in strain TA100 were 
also mutagenic, but-with reduced sensitivity, in the second strain TA1535. However, none of 
the epoxides in this study were found to be mutagenic in strains TA1537 and TA98 which 
detect frame-shift mutagens. The results indicate that the monosubstituted epoxides are the 
most potent mutagens and that the addition of a single methyl group to the oxirane ring 
could reduce or eliminate mutagenicity.  
Glatt et al. (1983) investigated 35 epoxides for mutagenicity, using reversion of his- 
Salmonella typhimurium TA98 and TA100 as the biological end-point. The results obtained 
were negative with the antibiotics oleandomycin, anticapsin and asperlin, the cardiotonic 
drug resibufogenin, the widely used parasympatholytic drugs butylscopolamine and 
scopolamine, the sedatives valtratum, didovaltratum and acevaltratum, the tranquilizer 
oxanamide as well as the drug metabolites carbamazepine 10,11-oxide and diethylstilbestrol 
ǂ and ǃ oxide. It was found that among the drugs and drug metabolites, only the cytostatic 
ethoglucide was markedly mutagenic. Three barbiturate epoxides showed very weak 
mutagenicity only at extremely high concentrations such that the effects were probably of 
low practical relevance. 
Later, the role of metabolism was also examined. For example, in vitro studies in rat-liver S9 
fractions which contain both microsomal and cytosolic detoxifying enzymes, such as EH 
and GST showed a decrease of bacterial genotoxicity (Flora et al., 1984). 
In vivo rodent bioassays on epoxides are not always positive and several epoxides are 
carcinogenic only at the point of administration. For example, it was found that when given 
by oral gavage, both ethylene oxide and propylene oxide caused late-onset tumors only in 
the rat fore-stomach. Again, when administered by inhalation, propylene oxide is a nasal 
carcinogen. On the other hand, in vivo studies in rat have shown that carbamazepine-10, 11-
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epoxide have the potential to initiate cellular damage if not adequately detoxified via 
conjugation with glutathione (Snodin, 2010). 
It was observed that owing to the role of metabolism, epoxides that are formed in vivo, such 
as those generated by epoxidation of alkenes and arenes, have a greater potential to cause 
adverse effects than preformed epoxides. This is because they are often produced at close 
proximity to their site of action and can thus reach their target quite readily. Therefore, this 
mechanism can explain the limited evidence of animal carcinogenicity tests for some 
epoxide compounds (Flora et al., 1984). 
3.5 Aromatic compounds  
Aromatic compounds involve various impurities; some impurities, such as fentanyl 
impurities, tremogenic impurities, p-nitrophenol (PNP) that have aromatic structure and 
aromatic amines will be discussed in this section. 
3.5.1 Aromatic amines 
Primary and secondary aromatic amines (generally after metabolism) generate an 
electrophilic species and thus produce a positive result in the Ames test when S9 mixture 
exists. 2, 4-Diaminotoluene, 2, 4-diaminoethylbenzene and a few amines containing a nitro-
group are direct mutagens. According to the in vivo carcinogenicity test, Ames positive 
compounds produce positive results, although p-anisidine and p-chloroaniline are 
noncarcinogenic in rodent bioassays (Snodin, 2010). 
3.5.2 p-Nitrophenol 
This synthetic chemical possesses fungicidal activity and is used as a starting material for 
the synthesis of some drugs. PNP and other substituted nitro benzenes after reduction 
produce arylhydroxylamines or hydroxamic esters which contain electrophilic nitrogen 
atoms. Thus, the electrophilic atoms might show genotoxic property for these compounds 
(Eichenbaum et al., 2009). 
It should be mentioned that negative results were obtained for Ames tests with the various 
strains of Salmonella typhimurium in the absence and presence of metabolic activation with 
rat liver S9. Another in vitro test, the hprt mutation test in Chinese hamster ovary (CHO) 
cells presented the same result as the Ames test for PNP. However, it was seen that PNP 
could induce chromosomal aberrations in mammalian cells, particularly in the presence of 
metabolic activation. Also, PNP was negative in the bone marrow micronucleus assay in 
mice at doses ranging from little toxicity to the maximum tolerated dose. In addition, PNP 
was cytotoxic to the bone marrow of male mice at tested doses (Eichenbaum et al., 2009). 
3.5.3 Fentanyl impurities 
The forced degradation of fentanyl produced seven aromatic degradants. Among these, 
propionanilide (PRP), N-phenyl-1-(2-phenylethyl)-piperidin-4-amine (PPA), 1-phenethyl-
1H-pyridin-2-one (1-PPO), fentanyl N-oxide, and 1-styryl-1H-pyridin-2-one (1-SPO) 
possibly indicate safety concerns. PPA was suggested as a potential genotoxic compound 
and the DNA damage in unscheduled DNA synthesis (UDS); the results were positive for 
PRP when in vitro rat hepatocytes were checked. In the ACD/Tox suite, 1-PPO and 1-SPO 
were identified as Ames hazards. These compounds were also predicted to have higher 
probabilities of being Ames positive (Garg et al., 2010). 
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3.5.4 Tremogenic impurities 
Tremogenic impurities comprise another sub-class of highly toxic impurities in APIs. Two 
pharmacopoeial APIs are known to have the potential to be contaminated with tremogenic 
impurities; pethidine and paroxetine (3-[(1, 3-benzodioxol-5-yloxy) methyl]-4-(4- 
fluorophenyl) piperidine). Pethidine can contain trace amounts of 1-methyl-4- phenyl-1, 2, 3, 
6-tetrahydropyridine (MPTP) derived from the hydrolytic degradation of side chain. 4-(4-
Fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine (FMTP) can be a potential 
reactant/intermediate in the synthesis of paroxetine. Owing to their toxicity to cells in the 
Substantia nigra, these highly potent impurities can induce Parkinsonism in humans. Thus, 
these compounds are known toxic impurities; however their genotoxicity remains unclear 
(Borman et al., 2008). 
3.6 β-lactam related impurities 
The following two impurities relate to the well known antibiotics cefotaxime and 
piperacillin. 
3.6.1 Dimeric impurity of cefotaxime 
The manufacturing and storage processes of cefotaxime produce various impurities such as 
dimeric impurity (Figure 2). 
 
 
 
 
Fig. 2. Structure of the dimeric impurity of cefotaxime 
The results of the mutagenesis assay indicate that the dimeric impurity is nonmutagenic to 
any test strains used in the presence and absence of S9 fraction. The results of the in vitro 
chromosomal assay show some chromosomal aberrations in cultured mammalian cells up to 
the maximum recommended concentration of 45 mg per culture, and no clastogenicity in 
mammalian cells in vitro (Agarwal et al., 2004).  
3.6.2 Piperacillin impurity-A 
The piperacillin impurity-A is a prominent degradation product of piperacillin that appears 
during manufacturing and storage processes (Figure 3). 
In all the strains of S. typhimurium; TA 97a, TA 98, TA 100, TA 102, and TA 1535, piperacillin 
impurity in the presence and absence of metabolic activation was found to be non-
mutagenic. Also, in vitro chromosomal aberration assay did not reveal any significant 
alterations. It is found that piperacillin impurity-A up to 5 mg/ml is nonclastogenic to CHO 
cell lines in the presence and absence of metabolic activation (Vijayan et al., 2007). 
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Fig. 3. Structure of piperacillin impurity-A 
4. Analytical approaches 
As discussed above, GIs possess unwanted effects and their contamination levels should be 
controlled. To achieve this, pharmaceutical R&D should employ robust and sensitive 
analytical methods for supporting drug development and monitoring the levels of GIs. In 
addition, analytical methods that are capable of measuring trace GIs must be employed to 
monitor the outcome of GIs during chemical synthesis. In recent years, manufacturers have 
developed sensitive methods for analyzing various GIs. In this context, conventional 
HPLC/UV methods are the first option for GIs analysis; however, these methods are often 
inadequate for the accurate determination of analytes at trace levels, depending on the 
properties of the analytes and sample matrices. Some of the challenges in the analytical 
determination of GIs in pharmaceuticals at trace levels include the diverse structural types 
of GIs, the unstable or chemically reactive nature of GIs, and an extremely high level of API 
as contaminant (Bai et al., 2010; Liu et al., 2010). 
4.1 HPLC methods 
In general, non-volatile GIs are analyzed by HPLC separation techniques, among which 
reversed phase HPLC (RPLC) is the most widely used separation mode (Elder et al., 2008a; 
Liu et al., 2010). A simple isocratic RPLC method has been employed for the determination 
of four genotoxic alkyl benzenesulfonates (ABSs) viz. methyl, ethyl, n-propyl, and isopropyl 
benzenesulfonates (MBS, EBS, NPBS, and IPBS) in amlodipine besylate (ADB). The RPLC is 
also applicable for sulfonate impurities with phenyl moiety such as methyl (MTs), ethyl 
(ETs) and isopropyl tosylates (ITs), methyl (MBs), ethyl (EBs), butyl (BBs) and isopropyl 
besylates (IBs) (Raman et al., 2008).  
Epoxides/hydroperoxides were analyzed using HPLC, and simple RPLC methods 
employing direct analysis (no sample preparation) were used for some of them. Yasueda et 
al. (2004) described an HPLC method for the determination of loteprednol impurities 
including a minor photolytic epoxide degradation product. Lacroix et al. (1992) reported an 
HPLC method for the determination of related substances, including the epoxide impurity  
of nadalol. A rapid resolution HPLC method was used for separating and quantifying the 
related impurities of atorvastatin, including two epoxide impurities atorvastatin epoxy 
www.intechopen.com
 
Toxicity and Drug Testing 
 
398 
dihydroxy and atorvastatin epoxy diketone. The limit of detection (LOD) and limit of 
quantitation (LOQ) for atorvastatin epoxy dihydroxy and atorvastatin epoxy diketone were  
0.025 and 0.075 g/ml, and 0.026 and 0.077 g/ml, respectively (Petkovska et al., 2008). Kong et 
al. (2001) determined two epoxide terpenoid impurities (actein and 27-deoxyactein) in a 
traditional Chinese herbal preparation (Cimicifuga foetida L.). Subsequently, they compared 
the HPLC results with evaporative light scattering detection (ELSD) with UV detection and 
found that the ELSD was significantly more sensitive. Sample pretreatment was performed 
prior to analysis owing to the complexity of the matrix. For the two epoxides the on-column 
sensitivity using UV detection was found to be 606 and 880 ng, respectively, whereas the 
sensitivity using ELSD was 40 and 33 ng, respectively. Using the optimized extraction 
procedure (methanol/water, 80/20 v/v) the levels of the two analytes were detected to be 
3.44±0.02% and 1.42±0.01%, respectively.  
A more common method for the analysis of alkylating impurities is by RPLC and MS 
detection; however, HPLC/UV methods are also carried out successfully for alkylating 
impurities. Valvo et al. (1997) reported an HPLC/UV method for the separation of 13 
impurities of verapamil; this method is claimed to be superior to both the existing 
pharmacopoeial methods for verapamil. Using this method, the LOD and LOQ were found 
to be 0.01% (0.05 g/ml) and 0.02% (1.0 g/ml), respectively. Also, the method was found to 
be sensitive to pH and mobile phase composition; however, it was in contrast to the findings 
of previous studies insensitive to stationary phase changes. 
Hydrophilic interaction liquid chromatography (HILIC) seems complementary to RPLC for 
the retention and separation of small molecule polar analytes, and has thus gained increasing 
attention recently. Good retention can be achieved for more polar analytes, which is not 
possible on RPLC columns. In the hydrazine group, the HILIC method was used in addition to 
the HPLC/UV and HPLC/MS methods (Elder et al., 2010c; Liu et al., 2010). An Indian research 
group reported the development and validation of a stability indicating HPLC method for the 
determination of the anti-tuberculosis drug, rizatriptan, and its degradation products, 
including a hydrazone impurity (Rao et al., 2006). Hmelnickis et al. (2008) used an HILIC 
method with different polar stationary phases (silica, cyano, amino, and the zwitterionic 
sulfobetaine) to separate six polar impurities, including 1,1,1-trimethylhydrazinium bromide, 
and demonstrated that HILIC was a useful alternative to reverse phase or ion chromatography 
(IC). Elder et al. (2010c) reported a table summarizing the various HPLC methods that were 
used in the literature for a wide range of drugs (Table 4). 
 
Active Potential 
Ingredient (API) 
Impurities Method details 
Allopurinol Hydrazine Derivatization using benzaldehyde, followed by LLE. 
HPLC with a 5 µm cyanosilyl stationary phase (R type) 
at 30 C. Mobile phase: 2-propanol/hexane (5/95, v/v). 
Flow rate 1. 5 ml/min; detection at 310 nm. 
API (general 
method) 
Hydrazine HPLC with (1) 5 µm ZIC HILIC (SeQuant), (2) 5 µm 
Develosil 100 Diol-5(Nomura), (3) 5 µm TSK-Gel 
Amide-80 (Tosoh Bioscience) and (4) 5 µm Zorbax NH2 
(Agilent) at different column temperatures (10–60 C). 
Mobile phase: TFA/water/ethanol (0.1/30/70, v/v). 
Flow rate 0.4 ml/min; CLND detection. 
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Active Potential 
Ingredient (API) 
Impurities Method details 
API (general 
method) 
Hydrazine (1) Derivatization using benzaldehyde. HPLC  
with no operating conditions reported. (2) LSE, 
followed by derivatization using benzaldehyde  
at lower temperatures. HPLC with no  
operating conditions reported. Detection at  
190 nm. 
Azelastine Impurity A: 
benzohydrazide, 
impurity B: 1-
benzoyl-2-[(4RS)-1-
methylhexahydro- 
1Hazepin-4yl] 
diazane 
HPLC with a 10µm cyanosilyl stationary phase (R) at 
30◦C. Mobile phase: pH 3.0 phosphate buffer and 
sodium octane sulphonic acid in water/acetonitrile 
(740/260, v/v). Flow rate 2.0 ml/min; detection at 210 
nm. 
Aryl hydrazones E-Aryl hydrazones HPLC with a 5 µm ODS stationary phase (Merck 
LiChrospher) at 25◦C. Mobile phase: 1mM pH 6.0 
phosphate buffer with 2 mM EDTA and methanol 
(40/60, v/v). Flow rate 1.0 ml/min; detection at 200–400 
nm (DAD).  
HPLC with a 5 µm phenyl hexyl stationary phase 
(Phenomenex Luna) at 25 C. Mobile phase: water and 
acetonitrile (50/50, v/v). Flow rate 0.3 ml/min. Positive 
and negative ion mode ESI with ion trap analyzer in 
SIM mode (M + H ion). Range 50–1000 m/z. Voltage 4 
kV, capillary temperature 250 C. 
Carbidopa Hydrazine Derivatization using benzaldehyde, followed by LLE. 
HPLC with a 5µm ODS stationary phase (Altima C18 or 
Hypersil ODS). Mobile phase: aqueous 0.03% EDTA 
and acetonitrile (300/700, v/v). Flow rate 1.0 ml/min; 
detection at 305 nm. 
Celecoxib Intermediate I: 4-
hydrazine benzene 
sulphonamide 
HPLC with a 4 µm ODS stationary phase (NovapaK 
C18). Mobile phase: pH 4.8 10mM phosphate buffer and 
acetonitrile (450/550, v/v). Flow rate 1.0 ml/min; 
detection at 252 nm. 
Copovidone Hydrazine Derivatization using benzaldehyde, followed by LLE. 
HPLC with a 5µm ODS stationary phase (Altima C18 or 
Hypersil ODS). Mobile phase: aqueous 0.03% EDTA 
and acetonitrile (300/700, v/v). Flow rate 1.0 ml/min; 
detection at 305 nm. 
Dihydralazine 
sulphate  
Hydrazine 
(impurity B) 
Derivatization using benzaldehyde, followed by LLE. 
HPLC with a 5µm ODS stationary phase (R type). 
Mobile phase: aqueous 0.03% EDTA and acetonitrile 
(300/700, v/v). Flow rate 1.0 ml/min; detection at 305 
nm. 
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Active Potential 
Ingredient (API) 
Impurities Method details 
Ebifuramin Impurity III: (+)-5-
morpholino methyl-
3-(5- 
nitrofurfurylidene 
amino)-oxazolidin- 
2-one
HPLC with a 5µm ODS stationary phase (Hypersil 
ODS). Mobile phase: acetonitrile/THF/pH 2.6 10mM 
dibutyl aminephosphate (15/5/80, v/v/v). Flow rate 
1.5 ml/min; detection at 254 nm. 
Hydralazine  Hydrazine Derivatization using benzaldehyde, followed by LLE. 
HPLC with a 5 µm ODS stationary phase (Altima C18 or 
Hypersil ODS). Mobile phase aqueous 0.03% EDTA and 
acetonitrile (300/700, v/v). Flow rate 1.0 ml/min; 
detection at 305 nm.
Hydralazine 
tablets 
Hydralazine 
hydrazone 
HPLC with a 10µm ODS stationary phase (Waters 
µBondapak) at room temperature. Mobile phase: 
acetonitrile/5 mM SDS/phosphoric acid (150/850/0.45, 
v/v/v). Flow rate 2.0 ml/min; detection at 220 nm. 
Isoniazid Impurity I: 1-
nicotinyl-2- lactosyl 
hydrazine 
HPLC with a 10 µm cyanopropyl stationary phase and a 
mobile phase consisting of a mixture of pH 3.5 10 mM 
acetate buffer and acetonitrile (95/5, v/v). Flow rate 
and detection wavelength not specified.
Isoniazid Hydrazine (I), 
isonictonic acid-N´-
(pyridyl-4- 
carbonyl) 
hydrazide (II), 
isonictonic acid-
pyridine-4- 
ylmethylene 
hydrazide (III), 
isonictonic acid 
ethylidene 
hydrazide) (IV) 
HPLC with a 5µm ODS stationary phase (Zorbax XDB 
Eclipse C18). Mobile phase water and acetonitrile 
(960/40, v/v). Flow rate 0.5 ml/min; detection at 252 
nm. 
Isoniazid Hydrazine HPLC-MS using negative electrospray ionization ESI 
with a Bruker Daltonics ToF. TLC with a silica gel F254 
TLC plate with a water/acetone/methanol/ethylacetate 
(10/20/20/50, v/v) mobile phase. Visualization using 
dimethyl aminobenzaldehyde solution; examination 
under daylight. 
Mildronate  Impurity 2: 1,1,1- 
trimethyl 
hydrazinium 
bromide 
HILIC with a 3 µm silica stationary phase (Atlantis 
HILIC silica, Alltima HP silica, and Spherisorb silica), 5 
µm cyano stationary phase (Discovery cyano), 3 µm 
amino stationary phase (Hypersil APS-1), and 5 µm 
sulfobetaine stationary phase (ZIC-HILIC) at 30 C. 
Mobile phase acetonitrile and 0.1% formic acid in water. 
Flow rate 0.2 ml/min with positive ion mode ESI 
detection at 20–35 kV using a triple quadra pole MS. 
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Active Potential 
Ingredient (API) 
Impurities Method details 
Nitrofural, 
nitrofurazone and 
nitrofuroxazide 
Hydrazine Derivatization using benzaldehyde, followed by LLE. 
HPLC with a 5µm ODS stationary phase (Altima C18 or 
Hypersil ODS). Mobile phase aqueous 0.03% EDTA and 
acetonitrile (300/700, v/v). Flow rate 1.0 ml/min; 
detection at 305 nm. 
Nitrofurazone  Impurity A: Bis- 
[(5-nitrofuran-2- yl) 
methylene] diazane
HPLC with a 5 µm ODS stationary phase (R type). 
Mobile phase acetonitrile/water (400/600, v/v). Flow 
rate 1.0 ml/min; detection at 310 nm. 
Povidone  Hydrazine Derivatization using benzaldehyde, followed by LLE. 
HPLC with a 5 µm ODS stationary phase (Altima C18, 
Hypersil ODS). Mobile phase aqueous 0.03% EDTA and 
acetonitrile (300/700, v/v). Flow rate 1.0 ml/min; 
detection at 305 nm. 
Pyridoxal 
isonicotinoyl 
hydrazone 
Hydrazine, 
isoniazid 
HPLC with 5 µm ODS (Nucleosil C18) and an isocratic 
mobile phase consisting of a mixture of methanol (A) 
and pH 3.0 10 mM phosphate buffer containing 5 mM 1-
heptane sulphonic acid and 2 mM EDTA (B) in a ratio of 
49/51, v/v. Flow rate 0.9 ml/min; detection at 297 and 
254 nm. 
Rifampicin Hydrazones: 
rifampicin quinone 
and 25-desacetyl 
rifampicin 
HPTLC with a silica gel 60 TLC plate (Merck) with a 
chloroform/methanol/water (80/20/2.5, v/v/v) mobile 
phase. Examined using Scanner II (Camag) at 330nm for 
25-desacetyl rifampicin and 490 nm for rifampicin 
quinone. 
Rifampicin Hydrazones: 
rifampicin quinone
HPLC with 10 µm silyl and 10µm nitrile stationary 
phases (Micro Pak Si-10 and MicroPak CN, respectively) 
and anisocratic mobile phase consisting of a mixture of 
chloroform and methanol of varying proportions. Flow 
rate 0.2–0.7 ml/min; detection at 334 nm. 
Rifampicin Hydrazones: 
rifampicin quinone, 
25-desacetyl-21- 
acetyl-rifampicin, 
25-desacetyl-23- 
acetyl-rifampicin 
HPLC with direct injection (DI) onto a 3 µm ODS 
stationary phase (Hypersil ODS) at 25 C and an 
isocratic mobile phase consisting of a mixture of pH 7.4 
50 mM phosphate buffer and acetonitrile (64/36, v/v). 
Flow rate 1.4 ml/min; detection at 240 nm. 
Alternatively, a 10 µm ODS stationary phase (Hypersil 
ODS) 
Rifampicin, 
isoniazid, 
pyrazinamide 
FDC 
Hydrazones: 
rifampicin quinone, 
desacetyl 
rifampicin, 
isonicotinyl 
hydrazone 
HPLC with a 5 µm L1 ODS stationary phase at 25 C 
and a gradient mobile phase consisting of varying 
mixtures of mobile phase A (pH 6.8 phosphate 
buffer/acetonitrile, 96/4, v/v) and mobile phase B (pH 
6.8 phosphate buffer/acetonitrile, 45/55, v/v or 55/45, 
v/v). Flow rate 1.5 or 1.0 ml/min; detection at 238 nm. 
Three L1 columns were evaluated: 1: Zorbax XDB, 2: 
Shim-pak CLC ODS and 3. Nucleosil EC 120-5. 
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Active Potential 
Ingredient (API) 
Impurities Method details 
Rizatriptan  Impurity I: 1-(4- 
hydrazinophenyl) 
methyl-1,2,3- 
triazole 
HPLC with a 5 µm nitrile stationary phase (Zorbax SB-
CN) at 25 C and a gradient mobile phase consisting of 
varying mixtures of pH 3.4 10 mM phosphate buffer, 
acetonitrile, and methanol. Flow rate 1.0 ml/min; 
detection at 225 nm. 
Vindesine 
sulphate  
Impurity C 
(desacetyl 
vinblastine 
hydrazide) 
HPLC with a 5 µm ODS stationary phase (R type) and a 
gradient mobile phase consisting of varying mixtures of 
pH 7.5 diethyl aminephosphate buffer and methanol. 
Flow rate 2.0 ml/min; detection at 270 nm. 
Table 4. Various HPLC methods used for a wide range of drugs; Abbreviations: DAD: diode 
array detection; EC: electrochemical detection; ESI: electrospray ionization; FDC: Fixed Dose 
Combination; HILIC: hydrophobic interaction liquid chromatography; LLE: liquid liquid 
extraction; LSE: liquid solid extraction; MS: mass spectroscopy; ODS: octadecyl silyl; SDS: 
sodium dodecyl sulphate; SIM: single ion monitoring; ToF: time of flight (Elder et al., 2010c). 
The use of water as sample diluent could pose a limitation for this separation technique, 
especially when high water content is required for dissolving the drug substance or the 
formulated drug product (Liu et al., 2010). 
4.2 GC methods 
GC methods are commonly used for the analysis of several volatile small molecule GIs. 
Some examples include the liquid injection technique and the headspace sampling 
technique. Liquid injection is prone to contamination in which injection of a large amount of 
non-volatile API can accumulate in the injector liner or on the head of the GC column, which 
can cause a sudden deterioration in method performance. Headspace injection, on the other 
hand, is desirable because it minimizes potential contamination of the injector or column by 
avoiding the introduction of a large quantity of API (Liu et al., 2010).  
David et al. (2010) proposed a method selection chart (Figure 4) containing GC or LC 
methods, both in combination with a single quadrupole mass spectrometer as detector. 
These methods applied for a wide range of analytes including sulphonates, alkyl halides, 
and epoxides. 
Nassar et al. (2009) developed a GC/MS method for residual levels of EMS in a mesylate salt 
of an API crystallized from ethanol. The method was capable of detecting EMS down to 
levels of 50-200 ppb. Subsequently, extraction techniques were developed for eliminating or 
reducing matrix related interference. Thus, Colon and Richoll (2005) surveyed liquid–liquid 
extraction (LLE), liquid phase micro-extraction (LPME), solid phase extraction (SPE), and 
solid phase micro-extraction (SPME) coupled with GC/MS and single ion-monitoring (SIM). 
Using these approaches, they developed limit tests (5 ppm) for some alkyl aryl esters of 
sulfonic acids. 
Similar attempts were made for reducing or eliminating the matrix effect for alkylating 
agents as well. In all these procedures, a specific physical property of the analyte not shared 
by the matrix was utilized, e.g. low boiling point and/or in the presence of halide atom 
(Elder et al., 2008a).  
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GC methods were rarely used for the analysis of epoxides/hydroperoxides, as compared to 
other impurities, owing to the size of molecule and the volatility properties within this 
group (Elder et al., 2010b). Klick (1995) used a GC method for the determination of residual 
levels of a chlorohydrin and the corresponding epoxide impurities in almokalant. Other 
literatures give an account of GC–MS methods for the analysis of volatile components in 
traditional Chinese herbal medicines (Yu et al., 2007; Guo et al., 2003).  
 
 
Fig. 4. Method selection chart for analyzing genotoxic impurities with GC/LC; 1AP-
ES/APCI: atmospheric pressure electrospray ionization/ atmospheric pressure chemical 
ionization; 2 If the analyte has sufficient vapor pressure in water or other low volatile 
solvent; 3 SHS: static headspace; 4 SPME: solid-phase micro-extraction; 5 DHS: dynamic 
headspace; 6 HILIC: hydrophobic interaction liquid chromatography; 7 derivatization-RPLC: 
reversed phase HPLC with precolumn derivatization; 8 Back-flush (CFT): capillary flow 
technology based back-flushing; 9 Deans 2DGC (CFT): capillary flow technology based two-
dimensional GC (Figure is reproduced from David et al., 2010).  
For the hydrazine group the normal flame ionization detection (FID) in GC analysis is not 
appropriate because these compounds possess no carbon atoms (Elder et al., 2010c). A GC 
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procedure involving the formation of a benzalazine derivative was developed for 
monitoring the residual levels of hydrazine in hydralazine and isoniazid APIs, tablets, 
combined tablets, syrups, and injectable products in which nitrogen selective detection was 
used (Matsui et al., 1983). 
In addition, Carlin et al. (1998) adapted a previously published method for monitoring a 
benzalazine derivative using GC with electron capture (EC) detection. The LOQ was 10 ppm 
and the method was linear over the range of 10-100 ppm. The inter-day residual standard 
deviation (RSD) based on six measurements at analyte levels of 10 ppm was 15%; however, 
this improved slightly at increased analyte concentrations of 25 and 100 ppm, to 9.5% and 
11.3%, respectively.  
Nevertheless, non-volatile API does not partition into the headspace and therefore does not 
enter the GC system; as a result, headspace injection becomes the preferred choice whenever 
possible (Liu et al., 2010).  
4.3 TLC/HPTLC methods 
In general practice, thin layer chromatography (TLC) is not preferred for the accurate 
determination of very low residual analyte level. However, this technique is still used for 
the determination of related substances in the pharmacopoeial monographs for amiodarone, 
bromazepam, carmustine, ifosamide, indoramin, and tolnaftate (Elder et al., 2008).  
Nevertheless, there are several examples of its use in association with determining levels of 
the epoxyl alkaloid, including scopolamine in extracts of Datura stramonium. Sass and Stutz 
(1981) used TLC to determine residual sulfur and nitrogen mustards (beta haloethyl 
compounds) in a variety of substrates in which the sensitivities in the microgram range were 
typically achievable. High performance thin layer chromatography (HPTLC) was used for 
monitoring the degradation products of rifampicin, including the hydrazones (25-desacetyl 
rifampicin (DAR)) and rifampicin quinone (RQU). Finally, it was concluded that the method 
is suitable for routine quality control and stability analyses, especially in the developing 
world (Jindal et al. 1994). 
4.4 Capillary electrophoresis methods 
Jouyban and Kenndler (2008) reviewed the applicability of capillary electrophoresis (CE) 
methods for the analysis of pharmaceutical impurities. In addition, they discussed the 
applications of these methods in various groups of compounds such as chemotherapeutic 
agents, central nervous system (CNS) drugs, histamine receptor and cardiovascular drugs.  
The main advantage of CE techniques is their selectivity; thus, they are suitable for the 
analysis of complex herbal products. Bempong et al. (1993) reported the separation of 13-cis 
and all-trans retinoic acid and their photo-degradation products (including all-trans-5, 6-
epoxy retinoic acid, 13-cis-5, 6-epoxy retinoic acid) using both capillary zone electrophoresis 
(CZE) and micellar electrokinetic chromatography (MEKC) methods. A Chinese research 
group reported the development of CE methods for the simultaneous determination of some 
hydrazine related impurities (Liu et al., 1996).  
Hansen and Sheribah (2005) evaluated a series of electrically driven separation techniques: 
CZE, MEKC, and microemulsion electrokinetic chromatography (MEEKC) for the 
determination of residual alkylating impurities in bromazepam API. However, the poor 
sensitivity of the techniques posed a problem even when specialized detection cells (e.g. 
bubble or Z-cells) were used. Mahuzier et al. (2001) demonstrated the poor sensitivity of CE 
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based methods, in comparison to other separation methods. The problem of limited 
sensitivity of CE methods can be solved either by the use of detection methods with 
sensitivity higher than UV absorption or by pre-concentration of the analytes (Jouyban and 
Kenndler, 2008).  
4.5 Enhancing methods 
Alternatively, the structure of the molecule as well as its properties can be altered to enhance 
detectability which in turn will help to achieve the desired sensitivity. This is especially true 
for GIs that lack structural features for sensitive detection (Bai et al., 2010; Liu et al., 2010). A 
number of general approaches could be considered, some of which are explained below: 
4.5.1 Chemical derivatization 
This method is generally used for stabilizing reactive GIs and for introducing a detection 
specific moiety for enhanced detection, i.e. chromophore for UV. Also, this method 
sometimes produces a single compound for several GIs; thus, it becomes non-specific which 
can be considered as an advantage in determining a group of structurally related 
compounds (Liu et al., 2010). Bai et al. (2010) introduced a chemical derivatization method 
for analyzing two alkyl halides and one epoxide. The objective of the three derivatization 
reactions is to generate a strong basic center by introducing an amine functional group. All 
three derivatization products are good candidates for electrospray ionization (ESI)-MS 
owing to the high proton affinity or the permanent charge.  
4.5.2 Coordination ion spray-MS 
Owing to their structural features, several analytes are not amenable to atmospheric 
pressure ionization methods, such as the ESI method. Alkali metal ions such as Li+, Na+, and 
K+ can form complexes with some organic molecules in the gas phase; this fact could be 
used as a solution for the analytes subjected previously (Liu et al., 2010). 
4.5.3 Matrix deactivation 
The matrix deactivation approach is a chemical approach to stabilize unstable/reactive 
analytes. It is based upon the hypothesis that the instability of certain GIs at trace level is 
caused by the reaction between the analytes and reactive species in the sample matrix. Thus, 
controlling the reactivity of the reactive species in the sample matrix would stabilize the 
unstable/reactive GI analytes (Liu et al., 2010).  
As an example the alkylators are reactive unknown impurities which possess mainly 
nucleophilic characteristics. Their reactivity can be attenuated by either protonation or 
scavenging approaches. Sun et al. (2010) reported a matrix deactivation methodology for 
improving the stability of unstable and reactive GIs for their trace analysis. This approach 
appears to be commonly applicable to techniques like direct GC–MS and LC–MS analyses, 
or  coupled with chemical derivatization as well.  
5. Genotoxicity prediction  
The concept of using structural alerts to predict potential genotoxic activity for identified 
impurities is now well established; however, the concordance between such alerts and 
biologically relevant genotoxic potential (in the context of genotoxic impurities) could be 
www.intechopen.com
 
Toxicity and Drug Testing 
 
406 
highly imperfect. Structural alerts are defined as molecular functionalities (structural 
features) that are known to cause toxicity, and their presence in a molecular structure alerts 
the investigator to the potential toxicities of the test chemical. Nevertheless, the assumption 
that any impurity with a structural alert is potentially DNA-reactive and thus subject to the 
default TTC limit may often lead to unnecessary restrictive limits. From a resource and time 
table viewpoint of a new drug production, the experimental determination of genotoxicity is 
not feasible for millions of drug candidates in the pharmaceutical industry. Thus, 
compounds identified as potential hazards by in silico methods would be high priority 
candidates for confirmatory laboratory testing (Kruhlak et al., 2007; Snodin, 2010).  
In silico toxicology is the application of computer technologies to analyze existing data, 
model, and predict the toxicological activity of a substance. In sequence, toxicologically 
based QSARs are mathematical equations used as a predictive technique to estimate the 
toxicity of new chemicals based upon a model of a training set of chemicals with known 
activity and a defined chemical space (Valerio, 2009).  
Ashby and Tennant (1991) reported some correlations of electrophilicity with DNA 
reactivity (assessed by Ames-testing data) for about 300 chemicals and elucidated the 
concept of structural alerts for genotoxic activity in the 1980s/1990s. Using a database of 
>4000 compounds, Sawatari et al. (2001) determined correlations between 44 substructures 
and bacterial mutagenicity data. A high proportion of genotoxic compounds were found for 
electrophilic reagents such as epoxides (63 %), aromatic nitro compounds (49 %), and 
primary alkyl monohalides (46 %). In a retrospective analysis of starting materials and 
intermediates involved in API syntheses, the most common structurally alerting groups 
were found to be aromatic amines, aromatic nitros, alkylating agents and Michael acceptors 
(Snodin, 2010). 
One of the strengths of QSAR models is that they contribute to a mechanistic understanding 
of the activity, and, at the same time, they constitute practical tools to predict the activity of 
further, untested chemicals solely based on chemical structure (Benigni et al., 2005). Another 
strength of QSAR models is that they are strictly data-driven, and are not based on a prior 
hypotheses. On the other hand, high-quality experimental data must be used to build the 
training data set. As error (e.g. incorrect molecular structure or erroneous data from 
toxicology studies of a chemical) is introduced into the model, amplification of that error is 
generated and represented in the prediction (Benigni et al., 2005; Valerio, 2009). 
Cunningham et al. (1998) investigated a SAR analysis of the mouse subset of the 
carcinogenic potency database (CPDB) which also included chemicals tested by the US 
national toxicology program (NTP). This database consisted of 627 chemicals tested in mice 
for carcinogenic activity with the tumorigenicity data being standardized and reported as 
TD50 values. In addition, MULTICASE software (www.multicase.com) was used to identify 
several structural features that are not explained by an electrophilic mechanism and which 
may be indicative of non-genotoxic chemicals or mechanisms involved in carcinogenesis 
other than mutations. The prediction capabilities of the system for identifying carcinogens 
and noncarcinogens were 70 % and 78 % for a modified validation set. 
Tafazoli et al. (1998) used the micronucleus (MN) test and the alkaline single cell gel 
electrophoresis (Comet) assay for analyzing potential mutagenicity, genotoxicty, and 
cytotoxicity of five chlorinated hydrocarbons. Using the generated data as well as the data 
of another five related chemicals that were investigated previously, a QSAR analysis was 
performed and the results indicated that LBC_C1 (longest carbon-chlorine bond length), MR 
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(molar refractivity), and ELUM0 (energy of the lowest unoccupied molecular orbital, 
indicating electrophilicity) were the most significant factors to be considered for 
discriminating between genotoxins and nongenotoxins. 
Benigni et al. (2005) showed that the QSAR models could correctly predict–– based only on 
the knowledge of the chemical structure––the genotoxicity of simple and unsaturated 
aldehydes. The active and inactive compounds were separated based on the hydrophobicity 
(log P) and bulkiness (MR) properties. 
Bercu et al. (2010) used in silico tools to predict the cancer potency (TD50) of a compound 
based on its structure. SAR models (classification/regression) were developed from the 
carcinogenicity potency database using MULTICASE and VISDOM (a Lilly Inc. in-house 
software). 
It is commonly accepted that the carcinogenicity of chemicals is owing to their genotoxicity 
and, in fact, the mutation and carcinogenesis data are practically coincident. Thus, the two 
endpoints were collapsed into one ‘‘genotoxicity’’ classification, in which QSAR analysis 
was applied. Now the question remains as to how to predict non-genotoxic carcinogenicity. 
In fact, it cannot be well approached until some mechanistic understanding of non-
genotoxic carcinogenesis is achieved. At this time, this approach is unable to grasp the 
structural features of non-genotoxic carcinogens (Ashby, 1990; Cunningham et al., 1998; 
Benigni et al., 2005).  
The other limitation to currently available QSARs is the lack of models for organometallics, 
complex mixtures (e.g. herbal extracts), and high molecular weight compounds such as 
polymers (Valerio, 2009). However, the QSAR predictive software offers a rapid, reliable, 
and cost effective method of identifying the potential risk of chemicals that are well 
represented in QSAR training data sets, even when experimental data are limited or lacking 
(Kruhlak et al., 2007). These models should be further developed/validated by employing 
new mechanistic findings and using newly reported experimental data. 
6. Conclusion  
Since 2007, following the EMEA suspension of the marketing authorization of viracept 
(nelfinavir mesylate), genotoxic impurities have become a common issue for health 
concerns. Thus, regulatory agencies have made several attempts to construct a systematic 
method for controlling and analyzing GIs. However, several points must be considered for 
achieving a general view on the regulation of GIs.  
One of the main problems is the very conservative limit regulated by agencies (1.5 µg/day). 
Bercu et al. (2009) calculated the permissible daily exposure (PDE) for EMS, which was the 
first GI of concern in 2007, as 0.104 mg/day. This value was found to be about 70-fold higher 
than the TTC level of 1.5 µg/day currently applied to EMS based on the generic linear back 
extrapolation model for genotoxins acting via non-threshold mechanisms. Other literatures 
highlighted this conservative limit as well (Gocke et al., 2009b; Elder et al., 2010a; Snodin, 
2010). In addition, Gocke et al. (2009b) reported that the accidental exposure of viracept 
patients did not result in an increased likelihood for adverse genotoxic, teratogenic or 
cancerogenic effects.  
In addition to the challenge of setting a more pragmatic limit for GIs, the development of 
extremely sensitive and robust analytical methods that can adequately monitor GIs at very 
low levels is very difficult. Also, the pharmaceutical industry has no long-term experience in 
the use of these methodologies within the factory setting. Thus, analysts make attempts to 
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determine a way for analyzing various GIs by using unique robust methods as far as 
possible. In this way, simple HPLC/UV or GC/FID methods are usually performed at the 
first stage, while more complicated LC/MS or LC/MS/MS methods are used as alternatives 
(Dobo et al., 2006; Elder et al., 2008b; Liu et al., 2010). 
Teasdale et al. (2009) studied the formation of sulfonate esters as a mechanistic view, and 
showed that when a slight excess of base is present, there is no discernible reaction rate to 
form the sulfonate ester and no mechanistic pathway to their formation. From this point of 
view, the formation of GIs and suspicious substances in the API syntheses can be easily 
avoided, and therefore this is the preferred option (Robinson, 2010). 
Finally, it can be mentioned that in such a situation, in silico approaches can prove to be a 
more effective solution in terms of time and cost for screening genotoxic compounds. As 
subjected by Luis and Valerio (2009), high-quality experimental data must be used. In 
addition, for non-genotoxic carcinogens, QSAR studies can provide a better understanding 
about the mechanism of carcinogenesis of these compounds. The in silico methods used in 
agencies have not been specified yet; however, by overcoming the limits these can become 
an innate part of regulatory systems. 
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